173 related articles for article (PubMed ID: 9585869)
1. Abacavir.
Foster RH; Faulds D
Drugs; 1998 May; 55(5):729-36; discussion 737-8. PubMed ID: 9585869
[TBL] [Abstract][Full Text] [Related]
2. Abacavir: a review of its clinical potential in patients with HIV infection.
Hervey PS; Perry CM
Drugs; 2000 Aug; 60(2):447-79. PubMed ID: 10983741
[TBL] [Abstract][Full Text] [Related]
3. Coming therapies: abacavir.
Staszewski S
Int J Clin Pract Suppl; 1999 Jun; 103():35-8. PubMed ID: 10622042
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine/zidovudine/abacavir: triple combination tablet.
Ibbotson T; Perry CM
Drugs; 2003; 63(11):1089-98; discussion 1099-1100. PubMed ID: 12749741
[TBL] [Abstract][Full Text] [Related]
5. Abacavir and lamivudine combination.
Somboonwit C; Kurtyka D; Velez AP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1599-606. PubMed ID: 19929448
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
Dart Trial Team
Trop Med Int Health; 2008 Jan; 13(1):6-16. PubMed ID: 18290996
[TBL] [Abstract][Full Text] [Related]
7. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
8. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
Wolbach J; Capoccia K
Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
[No Abstract] [Full Text] [Related]
9. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
Castillo SA; Hernandez JE; Brothers CH
Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966
[TBL] [Abstract][Full Text] [Related]
11. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
Jørgensen LB; Katzenstein TL; Gerstoft J; Mathiesen LR; Pedersen C; Nielsen C
Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938
[TBL] [Abstract][Full Text] [Related]
12. Once-daily abacavir in place of twice-daily administration.
Goedken AM; Herman RA
Ann Pharmacother; 2005; 39(7-8):1302-8. PubMed ID: 15956231
[TBL] [Abstract][Full Text] [Related]
13. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
15. [Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Aguirrebengoa K; Mallolas J; Uriz J; Torres Tortosa M
Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():3-9. PubMed ID: 9053024
[No Abstract] [Full Text] [Related]
16. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.
Harrigan PR; Stone C; Griffin P; Nájera I; Bloor S; Kemp S; Tisdale M; Larder B
J Infect Dis; 2000 Mar; 181(3):912-20. PubMed ID: 10720512
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team.
Kline MW; Blanchard S; Fletcher CV; Shenep JL; McKinney RE; Brundage RC; Culnane M; Van Dyke RB; Dankner WM; Kovacs A; McDowell JA; Hetherington S
Pediatrics; 1999 Apr; 103(4):e47. PubMed ID: 10103339
[TBL] [Abstract][Full Text] [Related]
18. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.
Bardsley-Elliot A; Perry CM
Paediatr Drugs; 2000; 2(5):373-407. PubMed ID: 11022799
[TBL] [Abstract][Full Text] [Related]
19. Abacavir: new preparation. Risks limit the value.
Prescrire Int; 2000 Jun; 9(47):67-9. PubMed ID: 11010740
[TBL] [Abstract][Full Text] [Related]
20. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.
van Praag RM; van Heeswijk RP; Jurriaans S; Lange JM; Hoetelmans RM; Prins JM
Clin Infect Dis; 2001 Oct; 33(8):e91-2. PubMed ID: 11565093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
